📣 VC round data is live. Check it out!
- Public Comps
- Ascentage Pharma Group
Ascentage Pharma Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ascentage Pharma Group and similar public comparables like Stoke Therapeutics, Cheezheng Tibetan Medicine, Zhejiang Wolwo Bio-Pharma, Sarepta Therapeutics and more.
Ascentage Pharma Group Overview
About Ascentage Pharma Group
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Founded
2009
HQ

Employees
567
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialAscentage Pharma Group Financials
Ascentage Pharma Group reported last 12-month revenue of $103M and negative EBITDA of ($153M).
In the same LTM period, Ascentage Pharma Group generated $95M in gross profit, ($153M) in EBITDA losses, and had net loss of ($170M).
Revenue (LTM)
Ascentage Pharma Group P&L
In the most recent fiscal year, Ascentage Pharma Group reported revenue of $85M and EBITDA of ($161M).
Ascentage Pharma Group is unprofitable as of last fiscal year, with gross margin of 91%, EBITDA margin of (191%), and net margin of (213%).
Financial data powered by Morningstar, Inc.
Ascentage Pharma Group Stock Performance
Ascentage Pharma Group has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Ascentage Pharma Group's stock price is $5.02.
Ascentage Pharma Group share price decreased by 11.9% in the last 30 days, and by 21.6% in the last year.
Ascentage Pharma Group has an EPS (earnings per share) of $-0.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -2.0% | -11.9% | -16.2% | -21.6% | $-0.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAscentage Pharma Group Valuation Multiples
Ascentage Pharma Group trades at 17.6x EV/Revenue multiple, and (11.8x) EV/EBITDA.
EV / Revenue (LTM)
Ascentage Pharma Group Financial Valuation Multiples
As of May 16, 2026, Ascentage Pharma Group has market cap of $2B and EV of $2B.
Ascentage Pharma Group has a P/E ratio of (11.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ascentage Pharma Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Ascentage Pharma Group Margins & Growth Rates
Ascentage Pharma Group grew revenue by 60% but EBITDA decreased by 17% in the last fiscal year.
In the most recent fiscal year, Ascentage Pharma Group reported gross margin of 91%, EBITDA margin of (191%), and net margin of (213%).
Ascentage Pharma Group Margins
Ascentage Pharma Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Ascentage Pharma Group Operational KPIs
Ascentage Pharma Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Ascentage Pharma Group's Rule of 40 is (39%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ascentage Pharma Group's Rule of X is 51% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Ascentage Pharma Group Competitors
Ascentage Pharma Group competitors include Stoke Therapeutics, Cheezheng Tibetan Medicine, Zhejiang Wolwo Bio-Pharma, Sarepta Therapeutics, Granules India, Intellia Therapeutics, AnaptysBio, InventisBio, ADMA Biologics and Guobang Pharma.
Most Ascentage Pharma Group public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 8.3x | 12.2x | (465.4x) | (19.9x) | |||
| 4.5x | — | 11.8x | — | |||
| 10.7x | 10.2x | 23.1x | — | |||
| 1.0x | 1.1x | (3.7x) | (12.7x) | |||
| 3.5x | 3.4x | 15.7x | 15.3x | |||
| 23.8x | 24.9x | (3.9x) | (3.9x) | |||
| 6.7x | 8.1x | 22.6x | 22.9x | |||
| 297.5x | 161.0x | (36.8x) | (36.6x) | |||
This data is available for Pro users. Sign up to see all Ascentage Pharma Group competitors and their valuation data. Start Free Trial | ||||||
Ascentage Pharma Group Funding History
Before going public, Ascentage Pharma Group raised $238M in total equity funding, across 3 rounds.
Ascentage Pharma Group Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ascentage Pharma Group
| When was Ascentage Pharma Group founded? | Ascentage Pharma Group was founded in 2009. |
| Where is Ascentage Pharma Group headquartered? | Ascentage Pharma Group is headquartered in China. |
| How many employees does Ascentage Pharma Group have? | As of today, Ascentage Pharma Group has over 567 employees. |
| Who is the CEO of Ascentage Pharma Group? | Ascentage Pharma Group's CEO is Dajun Yang. |
| Is Ascentage Pharma Group publicly listed? | Yes, Ascentage Pharma Group is a public company listed on HKEX. |
| What is the stock symbol of Ascentage Pharma Group? | Ascentage Pharma Group trades under 06855 ticker. |
| When did Ascentage Pharma Group go public? | Ascentage Pharma Group went public in 2019. |
| Who are competitors of Ascentage Pharma Group? | Ascentage Pharma Group main competitors include Stoke Therapeutics, Cheezheng Tibetan Medicine, Zhejiang Wolwo Bio-Pharma, Sarepta Therapeutics, Granules India, Intellia Therapeutics, AnaptysBio, InventisBio, ADMA Biologics, Guobang Pharma. |
| What is the current market cap of Ascentage Pharma Group? | Ascentage Pharma Group's current market cap is $2B. |
| What is the current revenue of Ascentage Pharma Group? | Ascentage Pharma Group's last 12 months revenue is $103M. |
| What is the current revenue growth of Ascentage Pharma Group? | Ascentage Pharma Group revenue growth (NTM/LTM) is 61%. |
| What is the current EV/Revenue multiple of Ascentage Pharma Group? | Current revenue multiple of Ascentage Pharma Group is 17.6x. |
| Is Ascentage Pharma Group profitable? | No, Ascentage Pharma Group is not profitable. |
| What is the current EBITDA of Ascentage Pharma Group? | Ascentage Pharma Group has negative EBITDA and is not profitable. |
| What is Ascentage Pharma Group's EBITDA margin? | Ascentage Pharma Group's last 12 months EBITDA margin is (149%). |
| What is the current EV/EBITDA multiple of Ascentage Pharma Group? | Current EBITDA multiple of Ascentage Pharma Group is (11.8x). |
| What is the current FCF of Ascentage Pharma Group? | Ascentage Pharma Group's last 12 months FCF is ($174M). |
| What is Ascentage Pharma Group's FCF margin? | Ascentage Pharma Group's last 12 months FCF margin is (169%). |
| What is the current EV/FCF multiple of Ascentage Pharma Group? | Current FCF multiple of Ascentage Pharma Group is (10.4x). |
| How many companies Ascentage Pharma Group has acquired to date? | Ascentage Pharma Group hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Ascentage Pharma Group has invested to date? | Ascentage Pharma Group hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Ascentage Pharma Group
Lists including Ascentage Pharma Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.